论文部分内容阅读
目的评价西布曲明对肥胖的2型糖尿病患者血糖的影响及安全性。方法为随机、双盲、安慰剂对照的临床研究。完成观察病例31例,其中西布曲明组15例,安慰剂组16例。结果西布曲明组的A1C用药第6个月末(7.08±1.69)%明显低于试验初期(7.69±1.26)%。在用药第5个月末的空腹血糖水平(7.81±1.55)mmol/L明显低于对照组(9.79±3.55)mmol/L。在用药第2个月末和第4个月末西布曲明组的体重〔分别为(69.04±8.78)?和(68.65±8.44)?〕明显低于对照组〔分别为(74.03±15.34)?和(74.07±15.44)?〕。西布曲明组在用药第3个月末甘油三酯〔(0.43±0.58)mmol/L〕和低密度脂蛋白〔(2.28±0.65)mmol/L〕明显低于安慰剂组〔分别为(0.80±0.72)mmol/L和(2.50±0.35)mmol/L〕。两组不良反应发生率没有显著差异。结论盐酸西布曲明可以进一步改善肥胖的2型糖尿病患者的血糖,糖尿病患者使用盐酸西布曲明安全有效。
Objective To evaluate the effect and safety of sibutramine on blood glucose in obese type 2 diabetic patients. Methods were randomized, double-blind, placebo-controlled clinical studies. Complete observation of 31 cases, including sibutramine group 15 cases, placebo group 16 cases. Results At the end of the 6th month of A1C administration in sibutramine group (7.08 ± 1.69)%, it was significantly lower than that in the initial test (7.69 ± 1.26)%. The fasting blood glucose level (7.81 ± 1.55) mmol / L at the end of the fifth month of treatment was significantly lower than that of the control group (9.79 ± 3.55) mmol / L. Body weight (69.04 ± 8.78 and 68.65 ± 8.44, respectively) in the sibutramine group at the end of the second and fourth months of treatment were significantly lower than those in the control group (74.03 ± 15.34 and (74.07 ± 15.44)?]. In the sibutramine group, triglyceride (0.43 ± 0.58 mmol / L) and LDL (2.28 ± 0.65 mmol / L) at the third month of treatment were significantly lower than those in the placebo group (0.80 ± 0.72) mmol / L and (2.50 ± 0.35) mmol / L〕. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Sibutramine hydrochloride can further improve the blood glucose in obese type 2 diabetic patients. It is safe and effective to use sibutramine hydrochloride in diabetic patients.